Optimizing cancer immunotherapy trials: Back to basics

European Journal of Immunology

Volumn 36, Issue 5, 2006, Pages 1070-1073

  Stevenson, Freda K ^a   Rice, Jason ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antigen processing and presentation; Cancer; Immunotherapy; T cells; Tumor immunology

Indexed keywords

AUTOANTIGEN; CANCER VACCINE; CD4 ANTIGEN; DNA; DNA VACCINE; EPITHELIAL CELL ADHESION MOLECULE; EPITOPE; HYBRID PROTEIN; MINOR HISTOCOMPATIBILITY ANTIGEN; TETANUS TOXIN; TUMOR ANTIGEN; VIRUS PROTEIN; VIRUS VECTOR;

ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG TARGETING; ELECTROPORATION; HELPER CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; LYMPHOMA; MOLECULAR DYNAMICS; NOTE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VACCINATION; VIRUS IMMUNITY;

ANTIGENS, NEOPLASM; CANCER VACCINES; CELL ADHESION MOLECULES; CLINICAL TRIALS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, SYNTHETIC;

EID: 33646592590     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200636085     Document Type: Note

References (21)

1. Hodgkin, P. D. and Basten, A., B cell activation, tolerance and antigen-presenting function. Curr. Opin. Immunol. 1995. 7: 121-129.
2. Fulcher, D. A., Lyons, A. B., Korn, S. L., Cook M. C., Koleda, C., Parish, C., Fazekas de St Groth, B. and Basten, A., The fate of self-reactive B cells depends primarily on the degree of antigen receptor engagement and availability of T cell help. J. Fxp. Med. 1996. 183: 2313-2328.
3. Avery, A. T. and Goebel, W. F., Chemo-immunological studies on conjugated carbohydrate proteins. II. Immunological specificity of synthetic sugar-protein antigens. J. Exp. Med. 1929. 50: 533-550.
4. Keene, J. A. and Forman, J., Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 1982. 155: 768-782.
5. von Herrath, M. G., Yokoyama, M., Dockter, J., Oldstone, M. B. and Whitton, J. L., CD4-deficient mice have reduced levels of memory cytotoxic T lymphocytes after immunization and show diminished resistance to subsequent virus challenge. J. Virol. 1996. 70: 1072-1079.
6. Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D. and Riddell, S. R., Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. 1995. 333: 1038-1044.
7. Sakaguchi, S., Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 2004. 22: 531-562.
8. Elia, L., Mennuni, C., Storto, M., Podda, S., Calvaruso, F., Salucci, V., Aurisicchio L. et al., Genetic vaccines against Ep-CAM break tolerance to self in a limited subset of subjects: Initial identification of predictive biomarkers. Eur. J. Immunol. 2006. 36 DOI 10.1002/eji.200635514
9. King, C. A., Spellerberg, M. B., Zhu, D., Rice, J., Sahota, S. S., Thompsett, A. R., Hamblin, T. J. et al. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat. Med. 1998. 4: 1281-1286.
10. Rice, J., de Lima, B., Stevenson, F. K. and Stevenson, P. G., A gamma-herpesvirus immune evasion gene allows tumor cells in vivo to escape attack by cytotoxic T cells specific for a tumor epitope. Eur. J. Immunol. 2002. 32: 3481-3487.
11. Rice, J., Buchan, S., Dewchand, H., Simpson, E. and Stevenson, F. K., DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire. J. Immunol. 2004. 173: 4492-4499.
12. Dupuis, M., Denis-Mize, K., Woo, C., Goldbeck, C., Selby, M. J., Chen, M., Otten, G. R. et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J. Immunol. 2000. 165: 2850-2858.
13. Buchan, S., Gronevik, E., Mathiesen, I., King, C. A., Stevenson, F. K. and Rice, J., Electroporation as a "Prime/Boost" Strategy for Naked DNA Vaccination against a Tumor Antigen. J. Immunol. 2005. 174: 6292-6298.
14. Otten, G., Schaefer, M., Doe, B., Liu, H., Srivastava, I, zur Megede, J., O'Hagan, D. et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004. 22: 2489-2493.
15. Kundig, T. M., Kalberer, C. P., Hengartner, H. and Zinkernagel, R. M., Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 1993. 11: 1154-1158.
16. Harrington, L. E., Most Rv, R., Whitton, J. L. and Ahmed, R., Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J. Virol. 2002. 76: 3329-3337.
17. Yewdell, J. W. and Bennink, J. R., Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 1999. 17: 51-88.
18. Snyder, H. L., Bacik, I., Yewdell, J. W., Behrens, T. W. and Bennink, J. R., Promiscuous liberation of MHC-class I-binding peptides from the C termini of membrane and soluble proteins in the secretory pathway. Eur. J. Immunol. 1998. 28: 1339-1346.
19. Rice, J., Elliott, T., Buchan, S. and Stevenson, F. K., DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines. J. Immunol. 2001. 167: 1558-1565.
20. Rice, J., Buchan, S. and Stevenson, F. K., Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumor antigen. J. Immunol. 2002. 169: 3908-3913.
21. Stevenson, F. K., Ottensmeier, C. H., Johnson, P., Zhu, D., Buchan, S. L., McCann, K. J., Roddick J. S. et al., DNA vaccines to attack cancer. Proc. Natl. Acad. Sci. USA 2004. 101 Suppl 2: 14646-14652.